Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Leukemia

  Free Subscription


Articles published in Am J Hematol

Retrieve available abstracts of 139 articles:
HTML format



Single Articles


    November 2021
  1. SANTOS FM, Ghelfond G, Seguro FS, Abdo ANR, et al
    Analyzing the impact of pregnancy on the outcomes of childbearing age women with chronic myeloid leukemia.
    Am J Hematol. 2021 Nov 25. doi: 10.1002/ajh.26424.
    PubMed    


  2. POPOVIC R, Dunbar F, Lu C, Robinson K, et al
    Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy.
    Am J Hematol. 2021 Nov 14. doi: 10.1002/ajh.26411.
    PubMed    


  3. CHO BS, Min GJ, Park SS, Yoon SY, et al
    Low-dose thymoglobulin for prevention of chronic graft-versus-host disease in transplantation from an HLA-matched sibling donor.
    Am J Hematol. 2021;96:1441-1449.
    PubMed     Abstract available


    October 2021
  4. SASAKI K, Kadia T, Begna K, DiNardo CD, et al
    Prediction of Early (4-week) Mortality in Acute Myeloid Leukemia with Intensive Chemotherapy.
    Am J Hematol. 2021 Oct 30. doi: 10.1002/ajh.26395.
    PubMed     Abstract available


  5. TROUSSARD X, Maitre E, Cornet E
    Hairy cell leukemia 2022: Update on diagnosis, risk-stratification, and treatment.
    Am J Hematol. 2021 Oct 28. doi: 10.1002/ajh.26390.
    PubMed     Abstract available


  6. MUCHTAR E, Koehler AB, Johnson MJ, Rabe KG, et al
    Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis.
    Am J Hematol. 2021 Oct 26. doi: 10.1002/ajh.26388.
    PubMed     Abstract available


  7. ZHANG Y, Li X, Weng X, Shen Y, et al
    Optimization of idarubicin and cytarabine induction regimen with homoharringtonine for newly diagnosed acute myeloid leukemia patients based on the peripheral blast clearance rate: a single-arm, phase 2 trial (RJ-AML 2014).
    Am J Hematol. 2021 Oct 23. doi: 10.1002/ajh.26386.
    PubMed     Abstract available


  8. HALLEK M, Al-Sawaf O
    Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures.
    Am J Hematol. 2021 Oct 9. doi: 10.1002/ajh.26367.
    PubMed     Abstract available


  9. HERZOG TZARFATI K, Gutwein O, Apel A, Rahimi-Levene N, et al
    BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.
    Am J Hematol. 2021;96:1195-1203.
    PubMed     Abstract available


  10. GRIMM J, Jentzsch M, Bill M, Backhaus D, et al
    Clinical implications of SRSF2 mutations in AML patients undergoing allogeneic stem cell transplantation.
    Am J Hematol. 2021;96:1287-1294.
    PubMed     Abstract available


    September 2021
  11. FURSTENAU M, Giza A, Stumpf T, Robrecht S, et al
    Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia.
    Am J Hematol. 2021 Sep 30. doi: 10.1002/ajh.26363.
    PubMed    


    August 2021
  12. SALIBA AN, Litzow MR, Gangat N, Al-Kali A, et al
    Outcomes of Venetoclax-Based Therapy in Chronic Phase and Blast Transformed Chronic Myelomonocytic Leukemia.
    Am J Hematol. 2021 Aug 24. doi: 10.1002/ajh.26334.
    PubMed    


  13. ZHOU B, Chu X, Tian H, Liu T, et al
    The Clinical Outcomes and Genomic Landscapes of Acute Lymphoblastic Leukemia Patients with E2A-PBX1: A 10-year Retrospective Study.
    Am J Hematol. 2021 Aug 18. doi: 10.1002/ajh.26324.
    PubMed     Abstract available


  14. ZHANG M, Xiao H, Shi J, Tan Y, et al
    Improved survival for young acute leukemia patients following a new donor hierarchy for allogeneic hematopoietic stem cell transplantation: a phase III randomized controlled study.
    Am J Hematol. 2021 Aug 9. doi: 10.1002/ajh.26317.
    PubMed     Abstract available


  15. ALWASH Y, Khoury JD, Tashakori M, Kanagal-Shamanna R, et al
    Development of TP53 Mutations Over the Course of Therapy for Acute Myeloid Leukemia.
    Am J Hematol. 2021 Aug 5. doi: 10.1002/ajh.26314.
    PubMed     Abstract available


  16. CHEN Z, Song J, Wang W, Bai J, et al
    A novel 4-mRNA signature predicts the overall survival in acute myeloid leukemia.
    Am J Hematol. 2021 Aug 2. doi: 10.1002/ajh.26309.
    PubMed     Abstract available


    July 2021
  17. VARETTONI M, Orlandi E, Zibellini S, Rossi M, et al
    Prognostic impact of somatic mutations on time to first treatment: results of targeted next-generation sequencing in 211 patients with early stage chronic lymphocytic leukemia.
    Am J Hematol. 2021 Jul 30. doi: 10.1002/ajh.26302.
    PubMed    


  18. KUSNE Y, Lasho T, Mangaonkar A, Tefferi A, et al
    Remarkable stability in clonal hematopoiesis involving leukemia-driver genes in patients without underlying myeloid neoplasms.
    Am J Hematol. 2021 Jul 21. doi: 10.1002/ajh.26297.
    PubMed    


  19. BROCCOLI A, Argnani L, Nanni L, Terragna C, et al
    The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: a thirty-year experience.
    Am J Hematol. 2021 Jul 10. doi: 10.1002/ajh.26287.
    PubMed     Abstract available


  20. GANGAT N, Guglielmelli P, Szuber N, Begna KH, et al
    Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
    Am J Hematol. 2021;96:781-789.
    PubMed     Abstract available


  21. HAYDU JE, Flamand Y, Vedula RS, Versluis J, et al
    Pretreatment clinical and genetic factors predict early post-treatment mortality in fit AML patients following induction.
    Am J Hematol. 2021;96:E259-E262.
    PubMed    


  22. JENTZSCH M, Grimm J, Bill M, Brauer D, et al
    Clinical value of the measurable residual disease status within the ELN2017 risk groups in AML patients undergoing allogeneic stem cell transplantation.
    Am J Hematol. 2021;96:E237-E239.
    PubMed    


  23. JOSHI SK, Sharzehi S, Pittsenbarger J, Bottomly D, et al
    A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.
    Am J Hematol. 2021;96:E226-E229.
    PubMed    


  24. OZGA M, Blachly J, Eisfeld AK, Grieselhuber N, et al
    Type of prior genotoxic insult determines the genomic characteristics of therapy-related myeloid neoplasms.
    Am J Hematol. 2021;96:E223-E225.
    PubMed    


    June 2021
  25. JABBOUR E, Patel K, Jain N, Duose D, et al
    Impact of Philadelphia chromosome-like alterations on efficacy and safety of blinatumomab in adults with relapsed/refractory acute lymphoblastic leukemia: a post hoc analysis from the phase 3 TOWER study.
    Am J Hematol. 2021 Jun 23. doi: 10.1002/ajh.26281.
    PubMed     Abstract available


  26. LAZARIAN G, Munger M, Quinquenel A, Dilhuydy MS, et al
    Clinical and biological characteristics of leukemia cutis in Chronic Lymphocytic Leukemia: a study of the French Innovative Leukemia Organization (FILO).
    Am J Hematol. 2021 Jun 21. doi: 10.1002/ajh.26274.
    PubMed    


  27. MOIGNET A, Pastoret C, Cartron G, Coppo P, et al
    Ruxolitinib for refractory large granular lymphocyte leukemia.
    Am J Hematol. 2021 Jun 16. doi: 10.1002/ajh.26275.
    PubMed    


  28. HELBIG DR, Abu-Zeinah G, Bhavsar E, Christos PJ, et al
    Outcomes in CLL patients with NOTCH1 regulatory pathway mutations.
    Am J Hematol. 2021;96:E187-E189.
    PubMed    


    May 2021
  29. AL-SAWAF O, Gentile B, Devine J, Zhang C, et al
    Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial.
    Am J Hematol. 2021 May 29. doi: 10.1002/ajh.26260.
    PubMed     Abstract available


  30. PICIOCCHI A, Messina M, Elia L, Vitale A, et al
    Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage Acute Lymphoblastic Leukemia patients treated in GIMEMA clinical trials since 1996.
    Am J Hematol. 2021 May 28. doi: 10.1002/ajh.26253.
    PubMed    


  31. ST MARTIN EC, Ferrer A, Wudhikarn K, Mangaonkar A, et al
    Clinical features and survival outcomes in patients with chronic myelomonocytic leukemia arising in the context of germline predisposition syndromes.
    Am J Hematol. 2021 May 24. doi: 10.1002/ajh.26250.
    PubMed    


  32. MOULIN C, Guillemin F, Remen T, Bouclet F, et al
    Clinical, biological, and molecular genetic features of Richter syndrome and prognostic significance: a study of the French Innovative Leukemia Organization.
    Am J Hematol. 2021 May 17. doi: 10.1002/ajh.26239.
    PubMed    


  33. JAIN N, Maiti A, Ravandi F, Konopleva M, et al
    Inotuzumab Ozogamicin with Bosutinib for Relapsed or Refractory Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Lymphoid Blast Phase of Chronic Myeloid Leukemia.
    Am J Hematol. 2021 May 15. doi: 10.1002/ajh.26238.
    PubMed     Abstract available


  34. MORABITO F, Del Poeta G, Mauro FR, Reda G, et al
    TP53 disruption as a risk factor in the era of targeted therapies: a multicenter retrospective study of 525 chronic lymphocytic leukemia cases.
    Am J Hematol. 2021 May 14. doi: 10.1002/ajh.26235.
    PubMed    


  35. HALL KH, Brooks A, Waller EK
    Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib.
    Am J Hematol. 2021 May 10. doi: 10.1002/ajh.26231.
    PubMed    


  36. MORABITO F, Tripepi G, Del Poeta G, Mauro FR, et al
    Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study.
    Am J Hematol. 2021;96:E168-E171.
    PubMed    


  37. OTHMAN TA, Mei M, Zhang J, Aldoss I, et al
    Rebound thrombocytosis is associated with response in AML patients treated with venetoclax and hypomethylating agents.
    Am J Hematol. 2021;96:E140-E143.
    PubMed    


    April 2021
  38. KADIA TM, Ravandi F, Borthakur G, Konopleva M, et al
    Long-term Results of Low-intensity Chemotherapy with Clofarabine or Cladribine Combined with Low-Dose Cytarabine Alternating with Decitabine in Older Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Am J Hematol. 2021 Apr 26. doi: 10.1002/ajh.26206.
    PubMed     Abstract available


  39. YILMAZ M, Daver N, Borthakur G, Kadia T, et al
    FLT3 inhibitor based induction and allogeneic stem cell transplant in complete remission 1 improve outcomes in patients with newly diagnosed Acute Myeloid Leukemia with very low FLT3 allelic burden.
    Am J Hematol. 2021 Apr 23. doi: 10.1002/ajh.26202.
    PubMed    


  40. MORABITO F, Tripepi G, Del Poeta G, Mauro FR, et al
    Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine. Results of study on 486 cases outside clinical trials.
    Am J Hematol. 2021 Apr 20. doi: 10.1002/ajh.26201.
    PubMed    


  41. JAMY O, Godby R, Sarmad R, Costa LJ, et al
    Survival of Chronic Myeloid Leukemia Patients in Comparison to the General Population in the Tyrosine Kinase Inhibitors Era: A US Population Based Study.
    Am J Hematol. 2021 Apr 17. doi: 10.1002/ajh.26195.
    PubMed    


  42. PELLAND-MARCOTTE MC, Kulkarni K, Athale UH, Pole JD, et al
    Thrombosis is associated with worse survival in children with acute lymphoblastic leukemia: a report from CYP-C.
    Am J Hematol. 2021 Apr 13. doi: 10.1002/ajh.26193.
    PubMed     Abstract available


  43. APEL A, Moshe Y, Ofran Y, Gural A, et al
    Venetoclax combinations induce high response rates in newly diagnosed Acute Myeloid Leukemia patients ineligible for intensive chemotherapy in routine practice.
    Am J Hematol. 2021 Apr 9. doi: 10.1002/ajh.26190.
    PubMed     Abstract available


  44. DONG N, Castillo Tokumori F, Isenalumhe L, Zhang Y, et al
    Large Granular Lymphocytic Leukemia - a Retrospective Study of 319 Cases.
    Am J Hematol. 2021 Apr 5. doi: 10.1002/ajh.26183.
    PubMed     Abstract available


  45. GANGAT N, Szuber N, Jawaid T, Hanson CA, et al
    Young platelet millionaires with essential thrombocythemia.
    Am J Hematol. 2021;96:E93-E95.
    PubMed    


  46. PARDANANI A
    Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management.
    Am J Hematol. 2021;96:508-525.
    PubMed     Abstract available


    March 2021
  47. SHORT NJ, Konopleva M, Kadia T, Kebriaei P, et al
    An Effective Chemotherapy-Free Regimen of Ponatinib plus Venetoclax for Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
    Am J Hematol. 2021 Mar 29. doi: 10.1002/ajh.26175.
    PubMed    


  48. AUDIL HY, Hampel PJ, Van Dyke DL, Achenbach SJ, et al
    The Prognostic Significance of del6q23 in Chronic Lymphocytic Leukemia.
    Am J Hematol. 2021 Mar 22. doi: 10.1002/ajh.26168.
    PubMed    


  49. LIU S, Deng B, Yin Z, Lin Y, et al
    Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation.
    Am J Hematol. 2021 Mar 16. doi: 10.1002/ajh.26160.
    PubMed     Abstract available


  50. SALHOTRA A, Aribi A, Ngo D, Zhang J, et al
    Outcome of secondary Acute Myeloid Leukemia treated with Hypomethylating agent plus Venetoclax (HMA-Ven) or Liposomal Daunorubicin-Cytarabine (CPX-351).
    Am J Hematol. 2021 Mar 14. doi: 10.1002/ajh.26157.
    PubMed    


  51. SASAKI K, Jabbour E, Short NJ, Jain N, et al
    Acute Lymphoblastic Leukemia: A Population- based Study of Outcome in the United States Based on the Surveillance, Epidemiology, and End Results (SEER) Database, 1980-2017.
    Am J Hematol. 2021 Mar 11. doi: 10.1002/ajh.26156.
    PubMed     Abstract available


  52. BALL BJ, Hsu M, Devlin SM, Arcila M, et al
    The prognosis and durable clearance of RAS mutations in patients with acute myeloid leukemia receiving induction chemotherapy.
    Am J Hematol. 2021 Mar 1. doi: 10.1002/ajh.26146.
    PubMed    


  53. WILHELMSSON M, Jahnukainen K, Winiarski J, Abrahamsson J, et al
    Hospitalizations in long-term survivors of childhood AML treated with allogeneic HCT-An Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study.
    Am J Hematol. 2021;96:E74-E77.
    PubMed    


  54. FERNANDES F, Ramalho R, Barreira R, Silveira M, et al
    Large granular lymphocytosis induced by dasatinib.
    Am J Hematol. 2021;96:395-396.
    PubMed    


    February 2021
  55. CHATZIDIMITRIOU C, Pappa V, Lakiotaki E, Plata E, et al
    Pancytopenia, eosinophilia and coagulation disorders in a patient with T-acute lymphoblastic leukemia in prolonged remission.
    Am J Hematol. 2021 Feb 27. doi: 10.1002/ajh.26145.
    PubMed    


  56. MORITA K, Jain N, Kantarjian H, Takahashi K, et al
    Outcome of T-cell Acute Lymphoblastic Leukemia/Lymphoma: Focus on Near-ETP Phenotype & Differential Impact of Nelarabine.
    Am J Hematol. 2021 Feb 27. doi: 10.1002/ajh.26144.
    PubMed     Abstract available


  57. MOU T, Pawitan Y, Stahl M, Vesterlund M, et al
    The transcriptome-wide landscape of molecular subtype-specific mRNA expression profiles in acute myeloid leukemia.
    Am J Hematol. 2021 Feb 24. doi: 10.1002/ajh.26141.
    PubMed     Abstract available


  58. FATHI AT, Stein EM, DiNardo CD, Levis MJ, et al
    Differentiation Syndrome with Lower-intensity Treatments for Acute Myeloid Leukemia.
    Am J Hematol. 2021 Feb 24. doi: 10.1002/ajh.26142.
    PubMed     Abstract available


  59. DAVER N, Salhotra A, Brandwein JM, Podoltsev NA, et al
    A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia.
    Am J Hematol. 2021 Feb 22. doi: 10.1002/ajh.26136.
    PubMed    


  60. VENUGOPAL S, Maiti A, DiNardo CD, Loghavi S, et al
    Decitabine and venetoclax for IDH1/2-mutated acute myeloid leukemia.
    Am J Hematol. 2021 Feb 13. doi: 10.1002/ajh.26122.
    PubMed    


  61. WANG S, Wang X, Ye C, Cheng H, et al
    Humanized CD19-targeted chimeric antigen receptor T (CAR-T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia.
    Am J Hematol. 2021 Feb 13. doi: 10.1002/ajh.26123.
    PubMed    


  62. BEGNA KH, Gangat N, Al-Kali A, Litzow MR, et al
    Acute myeloid leukemia after age 70 years: a retrospective comparison of survival following treatment with intensive vs HMA +/- venetoclax chemotherapy.
    Am J Hematol. 2021 Feb 2. doi: 10.1002/ajh.26112.
    PubMed    


  63. ZHENG H, Mineishi S, Claxton D, Zhu J, et al
    A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia.
    Am J Hematol. 2021;96:E46-E50.
    PubMed    


    January 2021
  64. RICHARDSON DR, Swoboda DM, Moore DT, Johnson SM, et al
    Genomic Characteristics and Prognostic Significance of Co-mutated ASXL1/SRSF2 Acute Myeloid Leukemia.
    Am J Hematol. 2021 Jan 27. doi: 10.1002/ajh.26110.
    PubMed     Abstract available


  65. HERGOTT CB, Dal Cin P, Hornick JL, Winer ES, et al
    Characteristic nuclear membrane ALK reactivity in chronic myelomonocytic leukemia with RANBP2-ALK fusion.
    Am J Hematol. 2021 Jan 25. doi: 10.1002/ajh.26107.
    PubMed    


  66. JONAS BA, Fisch SC, Rosenberg AS, Hoeg RT, et al
    Phase I Study of Escalating Doses of Carfilzomib with HyperCVAD in Patients with Newly Diagnosed Acute Lymphoblastic Leukemia.
    Am J Hematol. 2021 Jan 21. doi: 10.1002/ajh.26105.
    PubMed    


    December 2020
  67. BROWN JR, Walker SR, Heppler LN, Tyekucheva S, et al
    Targeting Constitutively Active STAT3 in Chronic Lymphocytic Leukemia: A Clinical Trial of the STAT3 Inhibitor Pyrimethamine with Pharmacodynamic Analyses.
    Am J Hematol. 2020 Dec 29. doi: 10.1002/ajh.26084.
    PubMed    


  68. CORTES JE, Mehta P
    Determination of Fitness and Therapeutic Options in Older Patients With Acute Myeloid Leukemia.
    Am J Hematol. 2020 Dec 23. doi: 10.1002/ajh.26079.
    PubMed     Abstract available


  69. WANG HP, Zhou YL, Huang X, Zhang Y, et al
    CDKN2A deletions are associated with poor outcomes in 101 adults with T-cell acute lymphoblastic leukemia.
    Am J Hematol. 2020 Dec 11. doi: 10.1002/ajh.26069.
    PubMed     Abstract available


  70. TESTI AM, Canichella M, Vitale A, Piciocchi A, et al
    Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase ii pediatric-like gimema lal-1308 trial.
    Am J Hematol. 2020 Dec 7. doi: 10.1002/ajh.26066.
    PubMed     Abstract available


  71. KOLLER PB, Zhang H, Kantarjian H, Jabbour E, et al
    GATA3 rs3824662A allele is associated with CRLF2 rearranged B-cell acute lymphoblastic leukemia in adults and adolescents and young adults (AYAs) and is associated with poor prognosis.
    Am J Hematol. 2020 Dec 4. doi: 10.1002/ajh.26065.
    PubMed    


  72. MAITI A, Qiao W, Sasaki K, Ravandi F, et al
    Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality.
    Am J Hematol. 2020 Dec 2. doi: 10.1002/ajh.26061.
    PubMed     Abstract available


  73. DIAO S, Nichols ED, DiNardo C, Konopleva M, et al
    Incidence of Tumor Lysis Syndrome in Patients with Acute Myeloid Leukemia Undergoing Low-Intensity Induction with Venetoclax.
    Am J Hematol. 2020 Dec 1. doi: 10.1002/ajh.26060.
    PubMed    


  74. PATEL S, Nayernama A, Jones SC, de Claro RA, et al
    BCR-ABL1 tyrosine kinase inhibitor-associated thyroid dysfunction: A review of cases reported to the FDA Adverse Event Reporting System and published in the literature.
    Am J Hematol. 2020;95:E332-E335.
    PubMed    


  75. SASAKI K, Montalban-Bravo G, Kanagal-Shamanna R, Jabbour E, et al
    Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3).
    Am J Hematol. 2020;95:E326-E329.
    PubMed    


  76. OFORI K, Soderquist CR, Murty VV, Park D, et al
    The clinical and pathological features of plasma cell myeloma post solid organ transplantation.
    Am J Hematol. 2020;95:1531-1541.
    PubMed     Abstract available


    November 2020
  77. ARSLAN S, Zhang J, Dhakal P, Moran J, et al
    Outcomes of Therapy with Venetoclax Combined with A Hypomethylating Agent in Favorable-Risk Acute Myeloid Leukemia.
    Am J Hematol. 2020 Nov 23. doi: 10.1002/ajh.26057.
    PubMed    


  78. SASAKI K, Jabbour EJ, Ravandi F, Konopleva M, et al
    The LEukemia Artificial Intelligence Program (LEAP) in Chronic Myeloid Leukemia in Chronic Phase: A Model to Improve Patient Outcomes.
    Am J Hematol. 2020 Nov 12. doi: 10.1002/ajh.26047.
    PubMed     Abstract available


  79. MONTALBAN-BRAVO G, Kanagal-Shamanna R, Guerra V, Ramos-Perez J, et al
    Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia.
    Am J Hematol. 2020 Nov 6. doi: 10.1002/ajh.26044.
    PubMed    


  80. GARCIA-MANERO G, Chien KS, Montalban-Bravo G
    Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
    Am J Hematol. 2020;95:1399-1420.
    PubMed     Abstract available


  81. MANNELLI F, Gianfaldoni G, Bencini S, Piccini M, et al
    Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in acute myeloid leukemia.
    Am J Hematol. 2020;95:1304-1313.
    PubMed     Abstract available


    October 2020
  82. POLLYEA DA, Pratz K, Letai A, Jonas BA, et al
    Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: long term follow-up from a Phase 1b study.
    Am J Hematol. 2020 Oct 29. doi: 10.1002/ajh.26039.
    PubMed     Abstract available


  83. BRANDWEIN JM, Hallett D, Karkhaneh M, Zhu N, et al
    An Evaluation of No-Treatment Decisions in Patients with Newly Diagnosed Acute Myeloid Leukemia.
    Am J Hematol. 2020 Oct 6. doi: 10.1002/ajh.26012.
    PubMed    


  84. RAUTENBERG C, Germing U, Stepanow S, Lauseker M, et al
    Influence of somatic mutations and pretransplant strategies in patients allografted for myelodysplastic syndrome or secondary acute myeloid leukemia.
    Am J Hematol. 2020 Oct 5. doi: 10.1002/ajh.26013.
    PubMed    



  85. Abstracts from the 2020 Lymphoma, Leukemia and Myeloma Congress October 21-24, 2020.
    Am J Hematol. 2020;95 Suppl 1:S3-S38.
    PubMed    


    September 2020
  86. POIANI M, Labopin M, Battipaglia G, Beelen DW, et al
    The impact of cytogenetic risk on the outcomes of Allogeneic Hematopoietic Cell Transplantation in patients with relapsed/refractory acute myeloid leukemia: on behalf of the Acute Leukemia Working Party (ALWP) of the EBMT.
    Am J Hematol. 2020 Sep 17. doi: 10.1002/ajh.26000.
    PubMed     Abstract available


  87. MARZOLLO A, Maestrini G, La Starza R, Elia L, et al
    A novel germline variant in PIK3R1 results in SHORT syndrome associated with TAL/LMO T-cell Acute Lymphoblastic Leukemia.
    Am J Hematol. 2020 Sep 16. doi: 10.1002/ajh.25998.
    PubMed    


  88. CHO BS, Min GJ, Park S, Park SS, et al
    Haploidentical versus matched unrelated donor transplantation for acute myeloid leukemia in remission: a prospective comparative study.
    Am J Hematol. 2020 Sep 9. doi: 10.1002/ajh.25993.
    PubMed     Abstract available


  89. BARON F, Labopin M, Ruggeri A, Sierra J, et al
    Impact of detectable measurable residual disease on umbilical cord blood transplantation.
    Am J Hematol. 2020;95:1057-1065.
    PubMed     Abstract available


  90. SMITH CJ, Kluck LA, Ruan GJ, Ashrani AA, et al
    The differential diagnosis of basophilia in patients undergoing BCR-ABL testing.
    Am J Hematol. 2020;95:E216-E217.
    PubMed    


  91. MARGOLSKEE E, Pillai V
    Loss of surface CD3 expression in allogeneic CAR T-cells.
    Am J Hematol. 2020;95:1115-1116.
    PubMed    


    August 2020
  92. PAGNANO KBB, Lopes ABP, Miranda EC, Delamain MT, et al
    Efficacy and Safety of Pioglitazone in a Phase 1/2 Imatinib Discontinuation Trial (EDI-PIO) in Chronic Myeloid Leukemia with Deep Molecular Response.
    Am J Hematol. 2020 Aug 30. doi: 10.1002/ajh.25986.
    PubMed    


  93. VAN ELSSEN CHMJ, Ciurea SO
    NK Cell Alloreactivity in Acute Myeloid Leukemia in the Post-transplant Cyclophosphamide Era.
    Am J Hematol. 2020 Aug 28. doi: 10.1002/ajh.25983.
    PubMed     Abstract available


  94. MORSIA E, McCullough K, Joshi M, Cook J, et al
    Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients.
    Am J Hematol. 2020 Aug 24. doi: 10.1002/ajh.25978.
    PubMed     Abstract available


  95. ESTEY EH
    Acute myeloid leukemia: 2021 update on risk-stratification and management.
    Am J Hematol. 2020 Aug 24. doi: 10.1002/ajh.25975.
    PubMed    


  96. SANDBERG Y, Verhoeven GT, Weerkamp F, Broyl A, et al
    Primary plasma cell leukemia mimicking a Pancoast tumor.
    Am J Hematol. 2020 Aug 24. doi: 10.1002/ajh.25977.
    PubMed    


  97. PLEYER C, Tian X, Rampertaap S, Mu R, et al
    A Phase II Study of Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with Chronic Lymphocytic Leukemia.
    Am J Hematol. 2020 Aug 18. doi: 10.1002/ajh.25968.
    PubMed    


  98. CANDONI A, Lazzarotto D, Ferrara F, Curti A, et al
    Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory t-cell acute lymphoblastic leukemia/lymphoma. the campus-all study.
    Am J Hematol. 2020 Aug 10. doi: 10.1002/ajh.25957.
    PubMed     Abstract available


  99. SAYGIN C, Larkin K, Blachly JS, Orwick S, et al
    A phase I study of lenalidomide plus chemotherapy with idarubicin and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
    Am J Hematol. 2020 Aug 10. doi: 10.1002/ajh.25958.
    PubMed     Abstract available


  100. JONDREVILLE L, Krzisch D, Chapiro E, Nguyen-Khac F, et al
    The complex karyotype and chronic lymphocytic leukemia. A review of the literature.
    Am J Hematol. 2020 Aug 10. doi: 10.1002/ajh.25956.
    PubMed     Abstract available


  101. JENG MY, Dutta R, Tan IT, Zhang TY, et al
    Improved Outcomes of Octogenarians and Nonagenarians with Acute Myeloid Leukemia in the Era of Novel Therapies.
    Am J Hematol. 2020 Aug 3. doi: 10.1002/ajh.25949.
    PubMed    


  102. KOFFMAN B, Mato A, Byrd JC, Danilov A, et al
    Management of CLL patients early in the COVID-19 pandemic: An international survey of CLL experts.
    Am J Hematol. 2020;95:E199-E203.
    PubMed    


  103. PATNAIK MM, Lasho T, Padron E, McCullough K, et al
    Special considerations in the management of patients with myelodysplastic myndrome / myeloproliferative neoplasm overlap syndromes during the SARS-CoV-2 pandemic.
    Am J Hematol. 2020;95:E203-E208.
    PubMed    


    July 2020
  104. BORTHAKUR G, Zeng Z, Cortes JE, Chen HC, et al
    Phase 1 Study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients.
    Am J Hematol. 2020 Jul 22. doi: 10.1002/ajh.25943.
    PubMed     Abstract available


  105. ABAZA Y, Kantarjian H, Alwash Y, Borthakur G, et al
    Phase I/II Study of Dasatinib in Combination with Decitabine in Patients with Accelerated or Blast Phase Chronic Myeloid Leukemia.
    Am J Hematol. 2020 Jul 18. doi: 10.1002/ajh.25939.
    PubMed     Abstract available


  106. DHOLARIA B, Labopin M, Angelucci E, Ciceri F, et al
    Impact of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning on Outcomes of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous Leukemia.
    Am J Hematol. 2020 Jul 13. doi: 10.1002/ajh.25934.
    PubMed     Abstract available


  107. ALDOSS I, Zhang J, Mei M, Al Malki MM, et al
    Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia.
    Am J Hematol. 2020 Jul 6. doi: 10.1002/ajh.25929.
    PubMed     Abstract available


  108. COLADO A, Marin Franco JL, Elias EE, Amondarain M, et al
    Second generation BTK inhibitors impair the anti-fungal response of macrophages and neutrophils.
    Am J Hematol. 2020;95:E174-E178.
    PubMed    


  109. KIM GYG, Burns J, Freyer CW, Hamilton KW, et al
    Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents.
    Am J Hematol. 2020;95:792-798.
    PubMed     Abstract available


    June 2020
  110. BOCK AM, Pollyea DA
    Venetoclax with Azacitidine for Two Younger Jehovah's Witness Patients with High Risk Acute Myeloid Leukemia.
    Am J Hematol. 2020 Jun 29. doi: 10.1002/ajh.25916.
    PubMed    


  111. DAGA S, Rosenberger A, Kashofer K, Heitzer E, et al
    Sensitive and broadly applicable residual disease detection in acute myeloid leukemia using flow cytometry-based leukemic cell enrichment followed by mutational profiling.
    Am J Hematol. 2020 Jun 29. doi: 10.1002/ajh.25918.
    PubMed     Abstract available


  112. OHANIAN M, Kantarjian HM, Shoukier M, Dellasala S, et al
    The Clinical Impact of Time to Response in De Novo Accelerated-Phase Chronic Myeloid Leukemia.
    Am J Hematol. 2020 Jun 17. doi: 10.1002/ajh.25907.
    PubMed     Abstract available


  113. IURLO A, Cattaneo D, Malato A, Accurso V, et al
    Low-Dose Ponatinib Is A Good Option In Chronic Myeloid Leukemia Patients Intolerant To Previous Tkis.
    Am J Hematol. 2020 Jun 17. doi: 10.1002/ajh.25908.
    PubMed    


  114. RUAN GJ, Smith CJ, Day C, Harmsen WS, et al
    A Population-based Study of Chronic Eosinophilic Leukemia-Not Otherwise Specified in the United States.
    Am J Hematol. 2020 Jun 13. doi: 10.1002/ajh.25906.
    PubMed    


  115. HASTINGS A, Apperley JF, Nadal-Melsio E, Brown L, et al
    Acute myeloid leukemia with a severe coagulopathy and t(8;16)(p11;p13).
    Am J Hematol. 2020 Jun 10. doi: 10.1002/ajh.25903.
    PubMed    


  116. JAIN P, Wang XI
    Carcinocythemia - cancer cell leukemia.
    Am J Hematol. 2020 Jun 10. doi: 10.1002/ajh.25902.
    PubMed    


  117. SAMRA B, Alotaibi AS, Short NJ, Khoury JD, et al
    Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
    Am J Hematol. 2020 Jun 5. doi: 10.1002/ajh.25896.
    PubMed    


  118. SUNG AD, Jauhari S, Siamakpour-Reihani S, Rao AV, et al
    Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects.
    Am J Hematol. 2020;95:662-671.
    PubMed     Abstract available


  119. PATEL SS, Weinberg OK
    Diagnostic workup of acute leukemias of ambiguous lineage.
    Am J Hematol. 2020;95:718-722.
    PubMed     Abstract available


    May 2020
  120. QASRAWI A, Ramlal R, Munker R, Hildebrandt GC, et al
    Prognostic impact of Philadelphia Chromosome in mixed phenotype acute leukemia (MPAL): a cancer registry analysis on real-world outcome.
    Am J Hematol. 2020 May 17. doi: 10.1002/ajh.25873.
    PubMed     Abstract available


  121. BYRNE M, Danielson N, Sengsayadeth S, Rasche A, et al
    The use of venetoclax-based salvage therapy for post-hematopoietic cell transplantation relapse of acute myeloid leukemia.
    Am J Hematol. 2020 May 10. doi: 10.1002/ajh.25859.
    PubMed     Abstract available


  122. AITKEN MJL, Benton CB, Wang F, Zhang J, et al
    33 years later: Two distinct cases of acute lymphoblastic leukemia in one patient.
    Am J Hematol. 2020 May 1. doi: 10.1002/ajh.25850.
    PubMed    


    April 2020
  123. SHORT NJ, Richard-Carpentier G, Kanagal-Shamanna R, Patel K, et al
    Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin.
    Am J Hematol. 2020 Apr 30. doi: 10.1002/ajh.25854.
    PubMed    


  124. CADENAS FL, Bua BR, Campelo MD, Rieu JB, et al
    A myeloid neoplasm with FIP1L1-PDGFRA presenting as acute myeloid leukemia.
    Am J Hematol. 2020 Apr 20. doi: 10.1002/ajh.25842.
    PubMed    


  125. CHRISTIAN S, Arain S, Patel P, Khan I, et al
    A Multi-institutional Comparison of Mitoxantrone, Etoposide, and Cytarabine (MEC) versus High-Dose Cytarabine and Mitoxantrone (Ara-C Couplets) Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia.
    Am J Hematol. 2020 Apr 20. doi: 10.1002/ajh.25838.
    PubMed     Abstract available


  126. MAFFINI E, Labopin M, Blaise D, Ciceri F, et al
    CD34+ cell dose effects on clinical outcomes after T-cell replete haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia using peripheral blood stem cells. A Study from the Acute Leukemia Working Party of the Euro
    Am J Hematol. 2020 Apr 17. doi: 10.1002/ajh.25826.
    PubMed     Abstract available


  127. KLEINSTERN G, O'Brien DR, Li X, Tian S, et al
    Tumor mutational load predicts time to first treatment in chronic lymphocytic leukemia (CLL) and monoclonal B-cell lymphocytosis beyond the CLL international prognostic index.
    Am J Hematol. 2020 Apr 12. doi: 10.1002/ajh.25831.
    PubMed     Abstract available


  128. GIARDINO S, Peffault de Latour R, Aljurf M, Eikema DJ, et al
    Outcome of Patients with Fanconi Anemia developing myelodysplasia and acute leukemia who received Allogeneic Hematopoietic Stem Cell Transplantation: A retrospective analysis on Behalf of EBMT group.
    Am J Hematol. 2020 Apr 8. doi: 10.1002/ajh.25810.
    PubMed     Abstract available


  129. ROGERS HJ, Wang X, Xie Y, Davis AR, et al
    Comparison of therapy-related and de novo core binding factor acute myeloid leukemia: a Bone Marrow Pathology Group study.
    Am J Hematol. 2020 Apr 6. doi: 10.1002/ajh.25814.
    PubMed     Abstract available


  130. MORSIA E, Reichard K, Pardanani A, Tefferi A, et al
    WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): A contemporary series from the Mayo Clinic.
    Am J Hematol. 2020 Apr 3. doi: 10.1002/ajh.25811.
    PubMed    


  131. ZHU HH, Yang MC, Wang F, Lou YJ, et al
    Identification of a novel NUP98-RARA fusion transcript as the 14(th) variant of acute promyelocytic leukemia.
    Am J Hematol. 2020 Apr 3. doi: 10.1002/ajh.25807.
    PubMed    


  132. LOSCOCCO GG, Mannelli F, Mannelli L, Vergoni F, et al
    A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: morphological and molecular characteristics of a highly aggressive disease.
    Am J Hematol. 2020 Apr 3. doi: 10.1002/ajh.25806.
    PubMed    


  133. KEMPS PG, Cleven AHG, van Wezel T, van Eijk R, et al
    B-cell lymphoblastic lymphoma with cutaneous involvement and a KMT2A gene rearrangement.
    Am J Hematol. 2020 Apr 3. doi: 10.1002/ajh.25801.
    PubMed    


  134. JABBOUR E, Kantarjian H
    Chronic Myeloid Leukemia: 2020 Update on Diagnosis, Therapy and Monitoring.
    Am J Hematol. 2020 Apr 2. doi: 10.1002/ajh.25792.
    PubMed     Abstract available


  135. OHANIAN M, Telouk P, Kornblau S, Albarede F, et al
    A heavy metal baseline score predicts outcome in acute myeloid leukemia.
    Am J Hematol. 2020;95:422-434.
    PubMed     Abstract available


  136. COLTRO G, Antelo G, Lasho TL, Finke CM, et al
    Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients.
    Am J Hematol. 2020;95:E86-E89.
    PubMed    


    March 2020
  137. BARON F, Efficace F, Cannella L, Muus P, et al
    Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukemia: Long-term follow up of a phase III study.
    Am J Hematol. 2020 Mar 31. doi: 10.1002/ajh.25795.
    PubMed     Abstract available


  138. GARCIA JS, Bhatt S, Fell G, Sperling AS, et al
    Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy.
    Am J Hematol. 2020;95:245-250.
    PubMed     Abstract available


    January 2020
  139. WILLIAMS AM, Baran AM, Schaffer M, Bushart J, et al
    Significant weight gain in CLL patients treated with Ibrutinib: A potentially deleterious consequence of therapy.
    Am J Hematol. 2020;95:E16-E18.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: